Jim Cramer on L'Oreal's Deal for Valeant's Skin Care Lines

Cramer looks back on his previous criticism of Valeant following L'Oreal deal.

Author:: Jim Cramer
Publish date:: Jan 10, 2017 12:10 PM EST

TheStreet's Jim Cramer admits he was wrong in underestimating the value of Valeant's (VRX) skin care lines. L'Oreal (LRLCY) just agreed to purchase CeraVe, Acne Free and Ambi for $1.3 billion. Now Cramer is questioning what else Valeant could sell as it tries to ease debt pressure.